- Global Pharma News & Resources

Global Neuroimmunology Drug Development Report 2022: Top 20 Neuroimmunology Products Forecast to be Worth $26.6 Billion by 2025 -

DUBLIN--(BUSINESS WIRE)--The "Neuroimmunology Drug Development - Thematic Research" report has been added to's offering.

The report provides an overview of neuroimmunology drug development within eight key indications across eight pharmaceutical markets.

The neuroimmune system is complex and a critical component in regulating nervous system health and disease. The publisher defines a neuroimmunology drug as an agent that aims to regulate immune system activity to treat neurological diseases with underlying immune pathologies. Various neuroimmunology therapeutic strategies are being studied and used in order to help treat neurological diseases, including drugs that target different types of cytokines, drugs that bind selectively to receptors, and drugs that affect the migration of immune cells.

Different types of molecules constituting neuroimmunology drugs are considered in this report including monoclonal antibodies, small molecules, recombinant products, and vaccines. This report focuses on neuroimmunology drug development within eight key indications (MS, NMOSD, GBS, CIDP, MG, AD/MCI, PD, and ALS) across eight major pharmaceutical markets (8MM: the US, 4EU, the UK, Japan, and China).

Key Highlights

  • Of the innovator products marketed for the eight key indications covered in this report, the majority are indicated for MS, followed by three each for NMOSD and AD, and two for MG. Most marketed neuroimmunology products are small molecules, followed by mAbs and recombinant proteins
  • According to the Drugs Database, there are currently almost 220 neuroimmunology drugs in Phase I, II, III, and later stages of development in the 8MM. The highest number of drugs are in development for AD, followed by amyotrophic lateral sclerosis (ALS), PD, MS and relapsing-remitting MS (RRMS)
  • The top 20 neuroimmunology products were worth $20.1 billion in 2020 and are expected to be worth $26.6 billion by 2025. Growth is driven primarily by the continued uptake of Ocrevus in MS and new launches across several indications. Extensive deal-making is occurring within the neuroimmunology drug space, with the top-valued deal being the acquisition of Alexion Pharmaceuticals by AstraZeneca, announced in December 2020
  • Of the ten key players involved in the neuroimmunology market, Roche, Biogen, AstraZeneca, Johnson & Johnson (J&J), Novartis, Sanofi, and UCB are all involved in marketing or developing neuroimmunology products across multiple neurological indications. The remaining three players are instead focused on neuroimmunological products in just one indication each-Merck KGaA in MS and Eisai and Lilly in AD


  • Overview of the neuroimmune system and its role in the pathology of eight key neurological diseases
  • Overview of key trends in the neuroimmunology drug development space
  • Evaluation of marketed and pipeline neuroimmunology drugs for the treatment of eight key neurological diseases, highlighting key mechanisms of action
  • Evaluation of clinical trials for marketed and pipeline neuroimmunology drugs
  • Market analysis of key neuroimmunology products in 2020 and 2025 plus an overview of key deals in the neuroimmunology space
  • Overview of opportunities and unmet needs in the neuroimmunology space
  • Analysis of companies developing neuroimmunology drugs, with a focus on major players

Key Topics Covered:

1. Preface

2. Executive Summary

2.1. Key Findings

3. Neuroimmunology Overview

3.1. The Neuroimmune System - Overview

3.2. What Is a Neuroimmunology Drug?

3.3. CNS Autoimmune Diseases

3.3.1. Overview of multiple sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

3.4. Peripheral Nerve Autoimmune Diseases

3.4.1. Overview of Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

3.5. Neuromuscular Junction Autoimmune Diseases

3.5.1. Overview of Myasthenia Gravis (MG)

3.6. Neurodegenerative Diseases

3.6.1. Overview of Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS)

4. Trends

4.1. Industry Trends

4.2. Macroeconomic Trends

4.3. Regulatory Trends

5. Value Chain

5.1. Neuroimmunology Value Chain - Autoimmune Diseases

5.2. Neuroimmunology Value Chain - Neurodegenerative Diseases

6. Marketed Drugs

6.1. Overview of Marketed Neuroimmunology Drugs

6.2. Marketed Neuroimmunology Drugs - Small Molecules

6.3. Marketed Neuroimmunology Drugs - Monoclonal Antibodies

6.4. Marketed Neuroimmunology Drugs - Recombinant Proteins

6.5. Other Marketed Neuroimmunology Drugs

7. Pipeline Products

7.1. Pipeline Neuroimmunology Overview

7.2. Pipeline Products - MS

7.3. Pipeline Products - AD

7.4. Pipeline Products - PD

7.5. Pipeline Products - ALS

7.6. Pipeline Products - NMOSD

7.7. Pipeline Products - MG

7.8. Pipeline Products - GBS & CIDP

8. Clinical Trials

8.1. Marketed Neuroimmunology Drugs - All Clinical Trials

8.2. Marketed Neuroimmunology Drugs - Ongoing or Planned Trials

8.3. Pipeline Neuroimmunology Drugs - All Clinical Trials

8.4. Pipeline Neuroimmunology Drugs - Ongoing or Planned Trials

9. Market Analysis

9.1. Top 20 Neuroimmunology Product Sales in 2020 and 2025

9.2. Top 10 M&A Deals in the Neuroimmunology Space

9.3. Top 10 Strategic Alliance Deals in the Neuroimmunology Space

10. Opportunities, Challenges, and Unmet Needs

10.1. Unmet Needs Surrounding Neuroimmunology Products - Gap Analysis

10.2. Unmet Needs - KOLs Perspective

11. Companies

  • F. Hoffmann-La Roche Ltd
  • Biogen
  • AstraZeneca Plc
  • J&J
  • Merck KGaA
  • Novartis AG
  • Sanofi
  • UCB SA
  • Eisai Co Ltd
  • Eli Lilly

For more information about this report visit

Source: GlobalData

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 13-Jun-2022